SCHEMBL4313389

SCHEMBL4313389

COCCN(C)Cc1ccc(/C=C/c2n[nH]c3ccccc23)c(NC(=O)c2sccc2C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 5/20 0.58
▸ AURKB Q96GD4 4/20 0.58
▸ NPC1 O15118 4/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ PARP1 P09874 1/20 0.35
▸ KDR P35968 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CASP3 P42574 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313400 1.00 AURKA (0.58) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4312994 0.90 AURKA (0.62) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4312987 0.90 AURKA (0.62) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL14989062 0.90 AURKA (0.48) AURKAAURKBSMN1; SMN2PARP1KDR
SCHEMBL4321146 0.88 AURKA (0.63) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4321138 0.88 AURKA (0.63) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4313957 0.87 AURKA (0.66) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL31824 0.87 AURKA (0.66) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4326156 0.87 AURKA (0.53) AURKAAURKBNPC1RAB9ASMN1; SMN2
SCHEMBL4326151 0.87 AURKA (0.53) AURKAAURKBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP claimed
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 — — CN claimed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US claimed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885NPC1 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback